Starting immediately, Sectra and private care provider Unilabs will offer preventive bone health testing for individuals with risk factors for osteoporosis, thereby enabling measures to be taken to reduce the risk of fractures. The analysis technology to be used by Unilabs will be provided by Sectra. One in two women in Sweden will suffer from a fracture due to osteoporosis, making osteoporosis…
Breast tomosynthesis imaging, Hologic calls it 3-D mammography, is proving to be the best modality to image breast cancer. ‘The Hologic tomosynthesis system has demonstrated superior clinical performance to conventional 2-D mammography in a number of metrics, in particular showing improved detection of invasive cancers and reductions in recall rate,’ the manufacturer reports, adding: ‘Now…
Tomosynthesis is a breast cancer screening and diagnostic modality that acquires images of a breast at multiple angles during a short scan. The individual images are then reconstructed into a series of thin, high-resolution slices typically one mm thick.
Using an iodinated contrast agent, I-View software on the Hologic tomosynthesis system enables the user to image the functional 2-D contrast uptake and the morphological mammography images in rapid sequence and combine these three image sets into a single co-registered study.
In a comprehensive modeling study, researchers from UC Davis and other institutions have found that breast cancer screening with digital mammography poses only a small risk of radiation-induced breast cancer for most women. However, the research showed increased risk for women with large breasts or breast implants, who must often receive extra screening views, increasing their radiation exposure.
Additional breast cancers found with MRI are sometimes larger and potentially more aggressive than those found on mammography, according to a study published online in the journal Radiology.
The mammography detection rate of an early-stage but potentially invasive type of breast cancer rises with age, according to a large new study from Germany published online in the journal Radiology.
An in-depth review of randomised trials on screening for breast, colorectal, cervical, prostate and lung cancers, published in the Journal of the Royal Society of Medicine, shows that the benefits of mammographic screening are likely to have been overestimated.
The Koning Breast CT (KBCT) system, which has been granted FDA approval, provides 3D breast of the entire breast from any orientation for diagnoses.
Women over the age of 50 are not only at higher risk of developing breast cancer but also osteoporosis. Would it not be practical to use the same method to detect both diseases early on? Definitely, decided Sectra, the Swedish company specialising in PACS and mammography systems.
It is tough enough to be a clinician reading dozens of mammograms every day to detect early signs of breast cancer. Now those same radiologists must become statisticians in order to decrypt dozens of studies, challenging whether it is worth reading mammograms in the first place. Report: John Brosky
MRI is increasingly relevant to cancer management, especially to detect breast carcinoma. Professor Christiane K Kuhl from the department of diagnostic and interventional radiology at the University of Aachen, Germany, strongly advocated in favour of MRI in breast cancer screening during a dedicated Satellite Symposium organised by Bracco at ECR 2015. Report: Mélisande Rouger
Carestream will show enhancements to its digital breast tomosynthesis (DBT) module including a slabbing tool, improved workflow capabilities and the display of DICOM-compliant 2D synthetic views (which are generated from the 3D dataset) at the 2015 European Conference of Radiology. The latest DBT module is currently available.
A panel of experts has recommended that existing programmes be phased out and that systematic screening programmes be replaced with systematic screening information that would give women the opportunity to make individual choices. Report: Mark Nicholls
A new study has suggested that mammography screening of healthy women can help to significantly reduce deaths from breast cancer. Much will now depend on new treatments and more systematic management of patients. Report: Mark Nicholls
Mammography scans with lower dose and higher contrast – that’s the declared goal of Dr Nik Hauser, Medical Director of the Women‘s Clinic and Director of the Interdisciplinary Breast Centre at Kantonsspital Baden, Switzerland, and Professor Marco Stampanoni of Paul Scherrer Institute in Villigen, Switzerland.
US-American researchers have shown that positron emission tomography (PET), a tried procedure, is a helpful modality to detect breast cancer.
Created by the Dutch industrialist family Hilekes, in 1993 Medicor expanded beyond the Benelux countries to enter the German-speaking world as Medicor Germany GmbH, selling contrast media injectors for CT, MRI and angiography.
Digital breast tomosynthesis offers a number of benefits over other modalities but challenges remain in its optimum clinical application.
Why is early detection of breast cancer so important? Professor Dr Walter Heindel, Director of the Institute of Clinical Radiology at University Hospital Münster, Germany, offers an unequivocal answer.
It may well be the first computer-aided detection (CAD) software that went to school with radiologists to study breast cancer.
In May, 2013, the U.S. Food and Drug Administration (FDA) finally took the training wheels off tomosynthesis by approving the use of Hologic's new C-View 2D imaging in place of conventional 2D mammograms previously required as part of a breast tomosynthesis screening exam.
RSNA opens a window for one week where companies can showcase the latest technologies ahead of regulatory approval. Fujifilm seized this opportunity to introduce the leading edge in tomosynthesis, the Amulet Innovality that it has launched in Europe, and that once given the green light by the FDA will come to America under the name Aspire Cristalle.
Research using an analytical health economics model has suggested the current system of screening within the UK’s National Health Service (NHS) is only moderately likely to be cost effective.
With the help of a commercially available CAD (computer-assisted diagnosis) programme, MRI can provide prognostic data on the development of distant metastases in the further course of breast cancer.